| 0.35 0 (0%) | 04-25 14:48 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.53 | 1-year : | 2.32 |
| Resists | First : | 1.31 | Second : | 1.99 |
| Pivot price | 0.55 |
|||
| Supports | First : | 0.21 | Second : | 0.18 |
| MAs | MA(5) : | 0.36  |
MA(20) : | 0.63 |
| MA(100) : | 1.59 |
MA(250) : | 3.11 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 14.7 |
D(3) : | 15.5 |
| RSI | RSI(14): 32.7 | |||
| 52-week | High : | 8.19 | Low : | 0.21 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ AMPE ] has closed above bottom band by 28.0%. Bollinger Bands are 20.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.48 - 0.48 | 0.48 - 0.48 |
| Low: | 0.28 - 0.28 | 0.28 - 0.28 |
| Close: | 0.35 - 0.35 | 0.35 - 0.35 |
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation; AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19; and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19. The company is headquartered in Englewood, Colorado.
Wed, 03 Apr 2024
Ampio Pharmaceuticals Received Audit Opinion with Going Concern Explanation - Longview News-Journal
Wed, 03 Apr 2024
Ampio Pharmaceuticals Received Audit Opinion with Going Concern Explanation - Yahoo Finance
Mon, 25 Mar 2024
Ampio Pharmaceuticals announces voluntary delisting and SEC deregistration (NYSE:AMPE) - Seeking Alpha
Mon, 25 Mar 2024
Ampio Pharmaceuticals to delist from NYSE American By Investing.com - Investing.com
Wed, 14 Feb 2024
Ampio Provides Update on Results from Pre-IND Enabling Studies - PR Newswire
Thu, 11 Jan 2024
Ampio Provides Litigation Update - Reports Settlement in Principle of Certain Pending Legal Actions - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 1 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 2.1 (%) |
| Held by Institutions | 0.3 (%) |
| Shares Short | 35 (K) |
| Shares Short P.Month | 41 (K) |
| EPS | -11.7 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.67 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -47.3 % |
| Return on Equity (ttm) | -91.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -11.65 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -11 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -0.03 |
| PEG Ratio | 0 |
| Price to Book value | 0.05 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.03 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|